Search results for "From ACP Internist"
6-food elimination diet may work for more than half of patients with eosinophilic esophagitis
Removing milk, wheat, soy, eggs, tree nuts/peanuts, and fish/shellfish from one's diet and then gradually reintroducing these food categories identified a single food trigger for 69% of participating patients with eosinophilic esophagitis, a retrospective study found.
https://gastroenterology.acponline.org/archives/2022/08/26/7.htm
26 Aug 2022
Guideline suggests prescription medications when lifestyle change ineffective for weight loss
For adults with obesity or overweight with weight-related complications, the American Gastroenterological Association found moderate certainty of benefit for four medications: semaglutide, liraglutide, phentermine-topiramate ER, or naltrexone-bupropion.
https://gastroenterology.acponline.org/archives/2022/10/28/6.htm
28 Oct 2022
European trial finds reduction in cancers but not deaths with invitation to colonoscopy screening
Healthy patients in Poland, Norway, and Sweden were randomized to usual care or an invitation to screening colonoscopy; only 42% of invited patients responded. The invited group had an 18% lower risk of colorectal cancer at 10 years compared to the usual care group.
https://gastroenterology.acponline.org/archives/2022/10/28/7.htm
28 Oct 2022
Continuing anti-TNF therapy in pregnancy appears beneficial for patients with IBD
A French target trial emulation, which refers to the use of observational data to mimic a randomized controlled trial, found that maternal relapse of inflammatory bowel disease (IBD) and premature births were less common when patients continued anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy than when the drugs were discontinued.
https://gastroenterology.acponline.org/archives/2022/10/28/8.htm
28 Oct 2022
Apixaban associated with lower risk of GI bleeding compared to other DOACs
Apixaban users experienced similar rates of ischemic stroke or systemic embolism, intracranial hemorrhage, and all-cause mortality as patients taking other direct oral anticoagulants (DOACs), a retrospective analysis found.
https://gastroenterology.acponline.org/archives/2022/11/18/6.htm
18 Nov 2022
Response to linaclotide for IBS constipation can still appear after four weeks
An industry-funded analysis of four randomized trials of linaclotide for irritable bowel syndrome (IBS) with constipation found that improvement in abdominal and bowel symptoms occurred after four weeks of treatment in 1 in 6 and 1 in 10 patients, respectively.
https://gastroenterology.acponline.org/archives/2022/12/23/6.htm
23 Dec 2022
ACG updates, reaffirms guidelines on evaluation, management of patients with celiac disease
The diagnostic approach to celiac disease in adults using serological and histologic data remains unchanged from the American College of Gastroenterology's (ACG) 2013 clinical guidelines.
https://gastroenterology.acponline.org/archives/2023/01/27/6.htm
27 Jan 2023
Use of warfarin down, DOACs up in commercially insured patients with cirrhosis, nonvalvular afib
While more than half of eligible patients with cirrhosis and concurrent nonvalvular atrial fibrillation did not receive anticoagulation between 2012 and 2019, use of direct oral anticoagulants (DOACs) increased substantially during that time, a recent study found.
https://gastroenterology.acponline.org/archives/2023/01/27/7.htm
27 Jan 2023
More tools available for treating IBS
Irritable bowel syndrome (IBS) is not a new disorder, but understanding of its pathophysiology and treatment has greatly progressed over the years.
https://gastroenterology.acponline.org/archives/2023/02/24/7.htm
24 Feb 2023
Improving celiac disease diagnosis
Celiac disease should be a differential diagnosis in patients with several classic clinical presentations, but atypical symptoms, including constipation, can cause doctors to overlook some patients.
https://gastroenterology.acponline.org/archives/2023/02/24/6.htm
24 Feb 2023